-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Downgrades Contineum Therapeutics to Neutral, Lowers Price Target to $14

Benzinga·10/14/2026 09:20:13
Listen to the news
Baird analyst Joel Beatty downgrades Contineum Therapeutics (NASDAQ:CTNM) from Outperform to Neutral and lowers the price target from $19 to $14.